Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort



Bonfá, Eloísa

Wojdyla, Daniel

Borba, Eduardo F.

Ramirez, Luis A.

Scherbarth, Hugo R.

Tavares Brenol, João C.

Chacón-Diaz, Rosa

Neira, Oscar J.

Berbotto, Guillermo A.

De La Torre, Ignacio Garcia

Acevedo-Vázquez, Eduardo M.

Massardo, Loret

Objective. To evaluate the beneficial effect of antimalarial treatment on lupus survival in a large, multiethnic, international longitudinal inception cohort. Methods. Socioeconomic and demographic characteristics, clinical manifestations, classification criteria, laboratory findings, and treatment variables were examined in patients with systemic lupus erythematosus (SLE) from the Grupo Latino Americano de Estudio del Lupus Eritematoso (GLADEL) cohort. The diagnosis of SLE, according to the American College of Rheumatology criteria, was assessed within 2 years of cohort entry. Cause of death was classified as active disease, infection, cardiovascular complications, thrombosis, malignancy, or other cause. Patients were subdivided by antimalarial use, grouped according to those who had received antimalarial drugs for at least 6 consecutive months (user) and those who had received antimalarial drugs for <6 consecutive months or who had never received antimalarial drugs (nonuser). Results